Liothyronine (Cytomel)
What studies of Liothyronine (Cytomel) found
At a glance, by condition
ME/CFS: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 2 findings, all C.
2 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Liothyronine (Cytomel) might help some people with ME/CFS, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Liothyronine (Cytomel) · ME/CFS is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
ME/CFS
Daily life and health overall
Daily functioning1 study · 1 (few people) person took Liothyronine (Cytomel) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · Twelve months later · 20 2g/d, added to continuing duloxetine (few people)
Daily functioning improved.
The evidence is very uncertain about the effect of liothyronine (Cytomel) on daily functioning in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
Successful treatment of chronic fatigue syndrome with duloxetine and trijodthyronine--a case study. (2008)
- People in the study
- 1 in the study
- Dose
- 20 2g/d, added to continuing duloxetine
- Outcome
- improvement in overall function at twelve months
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 1 (few people) person took Liothyronine (Cytomel) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · Twelve months later · 20 2g/d, added to continuing duloxetine (few people)
Overall symptoms improved.
The evidence is very uncertain about the effect of liothyronine (Cytomel) on overall symptoms in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
Successful treatment of chronic fatigue syndrome with duloxetine and trijodthyronine--a case study. (2008)
- People in the study
- 1 in the study
- Dose
- 20 2g/d, added to continuing duloxetine
- Outcome
- alleviation of psychic and somatic symptoms with combination therapy
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Side effects
No study of this treatment alone reported side effects we could read.
All papers
- Successful treatment of chronic fatigue syndrome with duloxetine and trijodthyronine--a case study.2008 · case report · 1 in the study
Summary
This case study reports one 26-year-old woman (Ms A) with chronic fatigue syndrome (cFS). No comparison group was used. She first received acyclovir 1.5 g/d for 10 days, which did not lead to clinical improvement, and amantadine 50 mg/d; in approximately 2 weeks tiredness and low energy improved, whereas myalgia did not change. Duloxetine was then given at 120 mg/d. Under duloxetine, most symptoms of cFS disappeared within 4 weeks and no adverse drug effects occurred; first improvements were a complete remission in body myalgia and a reduction in difficulties to concentrate in less than 4 weeks. Three months later, under continuous medication with duloxetine, she developed a relapse with daily somnolence, a strong feeling of tiredness, and the feeling of low energy; myalgia did not reappear. Trijodthyronine 20 2g/d was added to continuing duloxetine. Within 2 weeks, all symptoms disappeared almost completely. Twelve months later, she still continued to show improvement in her overall function. The authors do not state limitations.